Drug major lupin expects to launch nearly 25 products in the US market in 2016-17 that the company expects to be the key driver for its revenue growth, going forward.
“We expect to launch a good number of products between India and Gavis (US). We are hoping to launch 25 plus products, FDA permitting. So, a good number of launches that we expect for the year,” lupin CEO Vinita Gupta said in a conference call.
In the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzicom. The Mumbai-based firm expects to go ahead with launches on the dermatology front this year, she added.